Feasibility of Peritonectomy Associated with Intraperitoneal Hyperthermic Perfusion in Patients with Pseudomyxoma Peritonei

Abstract

The following conclusions can be drawn from this phase II clinical trial: 1) patients with pseudomyxoma peritonei originating from undifferentiated mucinous adenocarcinoma (peritoneal mucinous carcinomatosis), with complete distribution into the peritoneal cavity, are not eligible for the cytoreductive surgery plus intraperitoneal hyperthermic perfusion technique; 2) the presence of serous ascites would seem to exclude patients from the treatment; 3) cytoreductive surgery associated with intraperitoneal hyperthermic perfusion is the most suitable approach for patients with disseminated peritoneal adenomucinosis and in the intermediate group.

Cytoreductive Surgery With Intraperitoneal Chemohyperthermia for the Treatment of Pseudomyxoma Peritonei: A Prospective Study

“…11 Morbidity and mortality reported in other series using CRS and IPCH vary from 22 to 44 percent and 2.7 to 13.8 percent, respectively (Table 5). [16][17][18][19] Because of this high morbidity and mortality, many hospital centers are reluctant to undertake this treatment for patients with PMP. Our results are similar to those reported in other series.…”

“…Some authors favor multiple debulking surgeries with a tenyear reported survival of 32 to 60 percent. 14,15 Others recommend cytoreductive surgery (CRS) coupled with intraperitoneal chemohyperthermia (IPCH) [16][17][18][19] and reported a three-year to five-year actuarial survival rate of 74 to 86 percent for the most favorable pathologic type of PMP.…”

Progression of Pseudomyxoma Peritonei after Combined Modality Treatment: Management and Outcome

“…1 Aggressive cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment strategy for PMP with promising survival results. [2][3][4][5] The peritonectomy procedures are a useful tool to optimize resection of macroscopic peritoneal implants. HIPEC seems to reduce the recurrence or progression rate significantly by the cytotoxic effect on (microscopic) tumor residue, especially in patients with low-grade pathology and complete cytoreduction.…”

Abdominal Advanced Oncologic Surgery

“…Commonly, treatment regimens combine aggressive cytoreductive surgery with intraperitoneal chemotherapy. Cytoreductive surgery is the cornerstone of current treatment, while hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) is a promising strategy in suitable patients (Deraco et al, 2002) (Fig. 2).…”